secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-10-05T12:30:21+00:00
Accession:  0001437749-26-031978
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Moleculin Biotech 8-K cites Oct 5, 2026 investor presentation; exhibit content not included
--------------------------------------------------------------------------------

- Moleculin Biotech (MBRX) said it is using an attached corporate presentation posted on its website, dated October 5, 2026, per the filing signed by Jonathan P. Foster.
- Exhibit 99.1 contains no presentation text, slides, data tables, or figures - only the exhibit title - so no clinical, pipeline, or financial updates are available in this filing.
- No earnings, guidance, trial results, financing terms, or partnership details appear anywhere in the filing body or the appended exhibit.
- Investors seeking the actual corporate presentation content must retrieve it directly from the company's website; it cannot be summarized from this document.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926031978/0001437749-26-031978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926031978/mbrx20260928c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-031978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer